Albumin is clearly an extraordinary molecule of manifold functions and applications. Although the exact function of albumin has been debated, much of the present data support the notion that the principal role of albumin in the circulatory system is to aid in the transport, metabolism, and distribution of exogenous and endogenous ligands. The ability of albumin to act as an important extracellular antioxidant (Halliwell, 1988) or impart protection from free radicals, and other harmful chemical agents (Emerson, 1989) agrees well with the increased susceptibility of analbuminemic rats to cancer (Kakizoe and Sugimura, 1988). The expression and delivery of albumin to the circulatory system by the liver therefore seem appropriate. An overview of the prolific ligand-binding properties of albumin is summarized in Fig. 21. The positions of known binding sites for important pharmaceutical markers such as diazepam, ibuprofen, aspirin, and warfarin are illustrated. In addition, the important endogenous markers tryptophan, octanoate, and bilirubin are also shown. With the exception of the definitive positions of the long-chain fatty acids, most albumin-ligand chemistry can now be explained by the atomic coordinates derived from crystal structures. Knowledge of the atomic structure coupled with the current applications of genetic engineering, such as site-directed mutagenesis, promises to provide an even greater understanding of albumin chemistry. It is widely accepted in the pharmaceutical industry that the overall distribution, metabolism, and efficacy of many drugs can be altered based on their affinity to serum albumin. In addition, many promising new drugs are rendered ineffective because of their unusually high affinity for this abundant protein. Obviously, an understanding of the chemistry of the various classes of pharmaceutical interactions with albumin can suggest new approaches to drug therapy and design, placing albumin in its rightful place as the 'second step in rational drug design.' Application of albumin in other therapeutic approaches is widely known. Some studies have suggested that modified serum albumin may be used as a selective contrast agent for tumor detection and/or therapy (Sinn et al., 1990). Other studies have demonstrated that albumin may be used to deliver toxic compounds for elimination of Mycobacterium tuberculosis via receptor-mediated drug delivery (Majumdar and Basu, 1991). Recently, chimeric albumin molecules such as HSA-CD4 (Yeh et al., 1992) and HSA-Cu,Zn-superoxide dismutase (Mao and Poznansky, 1989) have been utilized to increase the half-life and distribution, and reduce the immunogenicity, of these potential protein therapeutics. Albumin has now been cloned and expressed in several bacterial and fungal systems. The primary motivation for many of these studies has been the potential of recombinant albumin to serve as a serum replacement product that is free from unwanted viral contaminants, e.g., hepatitis, herpes, and human immunodeficiency virus (HIV). The most successful production has been achieved by extracellular expression in yeast (Etcheverry et al., 1986; Hinchcliffe and Kenney, 1986; Kalman et al., 1990; Okabayashi et al., 1986; Quirk, et al., 1989; Sijmons et al., 1990; Sleep et al., 1991). Clearly, future scientific and therapeutic applications of albumin appear limitless. In conclusion, albumin may be unique among proteins in that so many scientists have spent the largest portion of their professional careers studying very specific aspects of this protein. New appreciation for the complexity and potential applications presented by the structure of albumin promises to consume the careers of many more scientists.